SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 224 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $772,594 | -48.0% | 28,023 | -43.3% | 0.00% | 0.0% |
| Q2 2023 | $1,485,505 | +17.6% | 49,418 | +41.7% | 0.00% | 0.0% |
| Q1 2023 | $1,263,703 | -17.6% | 34,880 | -18.9% | 0.00% | 0.0% |
| Q4 2022 | $1,534,060 | +24.1% | 43,007 | +17.8% | 0.00% | 0.0% |
| Q3 2022 | $1,236,000 | +28.0% | 36,507 | +9.2% | 0.00% | 0.0% |
| Q2 2022 | $966,000 | -43.3% | 33,424 | -36.6% | 0.00% | 0.0% |
| Q1 2022 | $1,704,000 | +24.7% | 52,724 | +12.4% | 0.00% | 0.0% |
| Q4 2021 | $1,367,000 | +1.2% | 46,898 | -7.4% | 0.00% | 0.0% |
| Q3 2021 | $1,351,000 | -12.6% | 50,669 | +0.9% | 0.00% | 0.0% |
| Q2 2021 | $1,546,000 | +189.5% | 50,235 | +146.8% | 0.00% | – |
| Q1 2021 | $534,000 | -19.8% | 20,358 | -23.0% | 0.00% | – |
| Q4 2020 | $666,000 | -16.6% | 26,432 | -31.1% | 0.00% | -100.0% |
| Q3 2020 | $799,000 | -35.6% | 38,353 | -26.6% | 0.00% | 0.0% |
| Q2 2020 | $1,241,000 | +96.4% | 52,253 | +48.8% | 0.00% | 0.0% |
| Q1 2020 | $632,000 | -57.8% | 35,123 | -44.4% | 0.00% | 0.0% |
| Q4 2019 | $1,497,000 | +10.6% | 63,120 | +28.2% | 0.00% | 0.0% |
| Q3 2019 | $1,353,000 | -21.5% | 49,245 | -5.4% | 0.00% | 0.0% |
| Q2 2019 | $1,724,000 | -0.6% | 52,063 | +5.3% | 0.00% | -50.0% |
| Q1 2019 | $1,734,000 | +69.5% | 49,457 | +60.6% | 0.00% | +100.0% |
| Q4 2018 | $1,023,000 | -70.6% | 30,798 | -55.5% | 0.00% | -66.7% |
| Q3 2018 | $3,484,000 | +57.6% | 69,181 | +87.4% | 0.00% | +50.0% |
| Q2 2018 | $2,210,000 | -60.7% | 36,924 | -69.9% | 0.00% | -60.0% |
| Q1 2018 | $5,623,000 | +7.8% | 122,773 | -6.2% | 0.01% | +25.0% |
| Q4 2017 | $5,214,000 | -7.0% | 130,825 | -6.6% | 0.00% | -20.0% |
| Q3 2017 | $5,604,000 | -13.4% | 140,095 | -6.7% | 0.01% | -16.7% |
| Q2 2017 | $6,473,000 | +191.3% | 150,176 | +111.6% | 0.01% | +200.0% |
| Q1 2017 | $2,222,000 | -15.8% | 70,973 | -32.1% | 0.00% | 0.0% |
| Q4 2016 | $2,638,000 | +110.0% | 104,480 | +105.7% | 0.00% | +100.0% |
| Q3 2016 | $1,256,000 | +118.8% | 50,789 | +80.1% | 0.00% | 0.0% |
| Q2 2016 | $574,000 | +21.9% | 28,200 | -8.6% | 0.00% | 0.0% |
| Q1 2016 | $471,000 | +511.7% | 30,851 | +441.4% | 0.00% | – |
| Q4 2015 | $77,000 | +5.5% | 5,698 | +8.0% | 0.00% | – |
| Q3 2015 | $73,000 | +10.6% | 5,275 | +35.3% | 0.00% | – |
| Q2 2015 | $66,000 | -34.0% | 3,900 | -52.8% | 0.00% | – |
| Q1 2015 | $100,000 | -19.4% | 8,264 | -44.7% | 0.00% | – |
| Q4 2014 | $124,000 | +416.7% | 14,931 | +442.6% | 0.00% | – |
| Q3 2014 | $24,000 | +700.0% | 2,752 | +1014.2% | 0.00% | – |
| Q2 2014 | $3,000 | -94.2% | 247 | -95.8% | 0.00% | – |
| Q1 2014 | $52,000 | -37.3% | 5,818 | -47.0% | 0.00% | – |
| Q4 2013 | $83,000 | +72.9% | 10,984 | +69.4% | 0.00% | – |
| Q3 2013 | $48,000 | +1100.0% | 6,485 | +932.6% | 0.00% | – |
| Q2 2013 | $4,000 | – | 628 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |